Lantern Pharma Inc.
04/30/2026 | Press release | Distributed by Public on 04/30/2026 04:18
Amendment to Annual Report (Form 10-K/A)
| ii | ||
| Cautionary Notice | ii | |
| PART III | ||
| Item 10. | Directors, Executive Officers and Corporate Governance. | 1 |
| Item 11. | Executive Compensation. | 3 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. | 6 |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence. | 8 |
| Item 14. | Principal Accountant Fees and Services. | 9 |
| PART IV | ||
| Item 15. | Exhibit and Financial Statement Schedules. | 10 |
| Item 16. | Form 10-K Summary. | 11 |
Lantern Pharma Inc. published this content on April 30, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 30, 2026 at 10:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]